Determining the carcinogenic potential of materials to which humans have significant exposures is an important, complex, and imperfect exercise. Not only are the methods for such determinations protracted and expensive and use large numbers of animals, extrapolation of data from such studies to human risk is imprecise. With improved understanding of oncogene activation and tumor suppressor gene inactivation, a number of animal models have been developed to dramatically reduce latency for chemically induced cancers and has led to the development and use of shorter carcinogenicity assays. Recent studies by a number of investigators suggest that specific gene signature patterns seen after short-term exposure of rats to test chemicals can predict long-term outcomes in cancer bioassays with relatively high accuracy. In addition, a recent survey performed by PhRMA member companies examined two hundred drug years to determine whether histological biomarkers seen at the end of a six-or twelve-month toxicology study in rats can predict the outcome of a two-year carcinogenicity study. With only a handful of exceptions, chronic studies appear capable of predicting effects at the end of two years with good accuracy. It is hoped that the combination of results from transgenic mouse assays and sixmonth rat studies will soon supplant the need for most two-year bioassays.
The two-species, two-year rodent bioassay has been the gold standard for carcinogenicity assessment for nearly half a century. In many ways, the assay served us well and has correctly identified nearly all known human carcinogens. Using rodents as a ''black box'' was necessary because mechanisms and pathways of carcinogenesis were unknown or poorly understood. Performing the assays using doses that in many cases are very large multiples of human exposure is necessary to compensate for the small number of animals studied relative to the size of exposed human populations.
If one were to design a perfect carcinogenicity study, it would have the following attributes. It would identify all materials that could potentially induce cancer in human beings. It would have 100% sensitivity and 100% specificity, that is, no false positives or false negatives. It would rank carcinogens in order of potency, since it is known that carcinogenic potency can vary over at least five orders of magnitude (Gold et al. 1984) . It would identify target organs and tissues, since some cancers like squamous cell carcinoma of the skin are rarely life threatening, whereas others, such as small cell carcinoma of the lung, have a poor prognosis. Lastly, the perfect test would provide results rapidly and at low cost.
NEAR-TERM SOLUTIONS
In 1997, constituent members of the International Conference on Harmonization signaled their willingness to accept short-term in vivo studies in place of traditional two-year studies in mice. The guidance suggested that acceptable substitutes consist of initiation/promotion studies, neonatal studies in rodents, and short-term (six-month) studies in transgenic mice. Subsequent survey studies have demonstrated the utility of this paradigm (Pritchard et al. 2003) . Although results in transgenic mouse studies have good concordance in predicting known or suspected human carcinogens and noncarcinogens (approximately 80%), on their own these assays fail to identify a number of human carcinogens. Although the combination of two traditional two-year bioassays in mice and rats successfully identify all human carcinogens, this combination has low specificity, that is, significant numbers of false positives. The combination of a transgenic mouse and a two-year rat bioassay gave the highest level of concordance (approximately 85%) and did not miss any known human carcinogens. In spite of these promising results, only about 20% of mouse cancer bioassays performed for submission to FDA's Center for Drug Evaluation and Research are in transgenic mice. This percentage has been nearly constant for the past eight years. A total of 179 transgenic protocols have been reviewed by the executive Carcinogen Assessment Committee, most in the p53 and rasH2 strains. One reason commonly cited for not using the shorter study is that the continuing requirement for a two-year rat study minimizes the advantage of a time-saving mouse study.
Clearly, the availability of a ''short-term'' rat bioassay in combination with a transgenic mouse study would be a major breakthrough in the nonclinical program of drug development.
In an effort to develop such an assay, thirteen PhRMA companies undertook an initiative to determine whether results from rat chronic studies could predict the outcome of two-year rat carcinogenicity bioassays. Results were derived from 194 compounds across 254 chronic studies and 194 two-year cancer bioassays. These studies were performed over a time period of more than twenty-five years. Preliminary results suggest that on an organ-by-organ basis, predictivity is poor. Also, presence of preneoplastic lesions at the end of six or twelve months failed to predict whether these lesions would progress to tumors. However, on a whole-animal basis, negative predictivity was good, namely, a lack of preneoplastic lesions (hyperplasia, hypertrophy, eosinophilic foci, basophilic foci) at the end of the chronic study predicted with good accuracy that the cancer bioassay would be negative. Twenty-one compounds were identified that were false negatives, that is, no preneoplastic lesions in the chronic study, yet the carcinogenicity bioassay was positive. These compounds had other characteristics that might exclude them from being considered in this type of extrapolation, namely, positive genotoxicity, positive results in the mouse bioassay, and/or perturbations in hormone levels. The entire database has been made available to FDA reviewers to independently verify these observations. It is estimated that if the database is verified and the paradigm adopted, the number of two-year rat studies could be reduced by approximately one half (Sistare 2009 ).
LONG-TERM SOLUTIONS
Although adoption of transgenic mouse bioassays and twelve-month rat ''predictor'' studies could in many instances dramatically influence nonclinical drug development timelines, these systems still essentially use animals as ''black boxes.'' The availability of ''omics'' technologies has provided tools to investigate molecular pathways of toxicity, including carcinogenicity. Cellular exposure to a carcinogen initiates a pathway(s) that gives cells a growth advantage, ultimately forming a colony (tumor) that can be recognized histologically. The use of toxigenomics tools may allow identification of these pathways after short-term drug exposures. Doing so would allow the identification of putative carcinogens as an end point in acute or subchronic studies.
Early indications suggest promise for this approach. For example Nie et al. (2006) treated rats for twenty-four hours with over one hundred ''paradigm compounds'' to develop a signature of nongenotoxic carcinogens. A gene expression database was built using cDNA miroarrays from liver samples. A training set of twenty-four nongenotoxic carcinogens and twenty-eight noncarcinogens was used to develop a six-gene expression signature. This biomarker was found to identify nongenotoxic carcinogens with 88.5% accuracy. Similarly, Fielden, Brennan, and Gollub (2007) treated rats for five days with one of one hundred structurally and mechanistically diverse nongenotoxic hepatocarcinogens and nonhepatocarcinogens. These studies were used to identify a novel multigene biomarker (i.e., signature) to predict the likelihood of nongenotoxic chemicals to induce liver tumors in longer-term studies. Independent validation of the signature on forty-seven test chemicals indicates an assay sensitivity and specificity of 86% and 81%, respectively.
SUMMARY
The two-species, two-year chronic bioassay has been the gold standard for determining potential carcinogenicity for nearly half a century. Although these bioassays have been useful tools, results are empirically derived, and little or no mechanistic understanding is gained from such studies. For the near-term future, it may be possible to assemble a ''carcinogenicity battery,'' that is, a series of assays and end points that are highly predictive of rodent carcinogenicity. The battery might include results from genetic toxicology studies, a transgenic mouse assay, a twelve-month rat study, and perhaps a consideration of structure/activity. In the longer term, use of omics technology might predict not just a hazard assessment for carcinogenicity, but also a mechanism-based prediction.
